QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Villeneuve, E. J Articles by Zed, P. J Search for Related Content PubMed PubMed Citation Articles by Villeneuve, E. J Articles by Zed, P. J

ASTHMA

Nebulized Magnesium Sulfate in the Management of Acute Exacerbations of Asthma

at time of writing, PharmD Student, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; now, Emergency Medicine/Critical Care Pharmacy Resident, University of Rochester Medical Center, Rochester, NY

Peter J Zed, BSc BSc(Pharm) PharmD FCSHP

Pharmacotherapeutic Specialist—Emergency Medicine, CSU Pharmaceutical Sciences, Vancouver General Hospital; Clinical Associate Professor, Faculty of Pharmaceutical Sciences; Associate Member, Division of Emergency Medicine, Faculty of Medicine, University of British Columbia

Reprints: Dr. Zed, CSU Pharmaceutical Sciences, Vancouver General Hospital, 855 W. 12th Ave., Vancouver, BC V5Z 1M9, Canada, fax 604/875-5267, e-mail zed{at}interchange.ubc.ca

OBJECTIVE: To evaluate the efficacy and safety of nebulized magnesium sulfate in the treatment of acute exacerbations of asthma.

DATA SOURCES: MEDLINE, EMBASE, and PubMed (all to October 2005) were searched using the key words magnesium, magnesium sulfate, magnesium compounds, nebulise, nebulize, vaporise, vaporize, nebulizers and vaporizers, aerosols, asthma, exacerbation, bronchial spasm, and bronchospasm.

STUDY SELECTION AND DATA EXTRACTION: Prospective, randomized, controlled trials that evaluated efficacy and safety endpoints of nebulized magnesium sulfate in the management of acute exacerbations of asthma were included. All studies were evaluated independently by both authors. Efficacy outcomes included pulmonary function, clinical disease severity (as defined by each study), and rate of hospitalization. Safety outcomes were as described by each trial.

DATA SYNTHESIS: Six prospective trials met the study criteria. Nebulized magnesium alone failed to demonstrate any benefit compared with ß₂-agonists alone at improving pulmonary function. In trials in which nebulized magnesium was used as a vehicle for albuterol, there appear to be additional benefits to albuterol therapy in terms of improvements in pulmonary function in a population with mild-to-moderate asthma. The heterogeneous patient populations, study designs, magnesium doses, and the delivery methods preclude the extrapolation of these results to current clinical practice.

CONCLUSIONS: The studies included in this review fail to clarify the role of nebulized magnesium sulfate; therefore, this therapy cannot be recommended at this time. Future studies evaluating the role of nebulized magnesium as an adjunct therapy to ß₂-agonist, anticholinergic, and corticosteroid therapy are necessary to determine whether a clinically relevant benefit of this intervention exists.

Key Words: asthma, inhalation, magnesium, nebulized.

Published Online, May 30, 2006. www.theannals.com, DOI 10.1345/aph.1G496

This article has been cited by other articles:

				S Mohammed and S Goodacre Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis Emerg. Med. J., December 1, 2007; 24(12): 823 - 830. [Abstract] [Full Text] [PDF]